Back to top
more

Stryker (SYK)

(Delayed Data from NYSE)

$377.58 USD

377.58
972,333

+1.21 (0.32%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $377.57 -0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

The Rise of Robots in Surgery Puts Spotlight on These 3 Stocks

by Zacks Equity Research

A number of MedTech companies are currently attempting to gain ground within the robotics-aided healthcare market.

Trina Mukherjee headshot

3D Printing Gaining Popularity: 3 MedTech Stocks to Watch

by Trina Mukherjee

In the near future, there is a probability of 3D-printed implantable organs becoming a reality, thereby increasing the number of lives saved.

Sweta Jaiswal, FRM headshot

ETFs to Gain as Surgical Robots Rise in Popularity

by Sweta Jaiswal, FRM

We highlight ETFs which are set to gain from an expanding surgical robotic market on factors like growing demand for automation in healthcare, rising cases of chronic diseases and ageing population.

Zacks Equity Research

Here's Why Investors Should Retain Accuray (ARAY) Stock Now

by Zacks Equity Research

Accuray (ARAY) slashes fiscal 2020 revenue guidance owing to tariffs in China.

Zacks Equity Research

Stock Market News for Sep 5, 2019

by Zacks Equity Research

Major indexes ended in the green on Wednesday after the Fed???s Beige Book revealed that the U.S. economy expanded modestly through August-end.

Zacks Equity Research

Stryker's Mobius Imaging Buyout to Boost Its Spine Division

by Zacks Equity Research

Stryker (SYK) expects the buyout to remain neutral to its 2019 earnings.

Supriyo Bose headshot

5 ROE Stocks to Profit as Trade War Flip-Flops Rattle Market

by Supriyo Bose

ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.

Zacks Equity Research

Veeva Systems (VEEV) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Veeva Systems (VEEV) issues a strong guidance for fiscal 2020.

Zacks Equity Research

Phibro's (PAHC) Q4 Earnings Miss Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Phibro's (PAHC) revenue decline across two core segments and contraction in operating margin are concerning.

Zacks Equity Research

Stryker (SYK) Up 0.7% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Stryker (SYK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Add Stryker (SYK) to Your Portfolio

by Zacks Equity Research

Stryker (SYK) gains from core segments in the second quarter of 2019.

Zacks Equity Research

Here's Why You Should Snap Up Baxter International (BAX) Now

by Zacks Equity Research

For 2019, Baxter (BAX) expects adjusted earnings per share within $3.34-$3.40.

Zacks Equity Research

Accuray (ARAY) Reports Loss in Q4, Revenues Beat Estimates

by Zacks Equity Research

Accuray (ARAY) expects fiscal 2020 revenues to be impacted by China tariffs.

Zacks Equity Research

Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (SYK) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Baxter's PrisMax Adopted by Hamilton Health Care System

by Zacks Equity Research

Baxter's (BAX) PrisMax System first adopted by Hamilton Health, which in turn is expected to enhance patient care.

Zacks Equity Research

National Vision (EYE) Q2 Earnings Lag Estimates, Margins Down

by Zacks Equity Research

National Vision's (EYE) Military brand registers robust growth while other brands fail to impress.

Zacks Equity Research

Glaukos (GKOS) Q2 Loss Wider Than Estimates, '19 View Raised

by Zacks Equity Research

Glaukos (GKOS) raises 2019 revenues view; optimistic about Avedro buyout.

Zacks Equity Research

Nevro (NVRO) Q2 Loss Wider Than Expected, Revenues Down Y/Y

by Zacks Equity Research

Nevro (NVRO) sees dismal segmental performance in Q2.

Zacks Equity Research

Inogen (INGN) Q2 Earnings Miss Estimates, 2019 View Lowered

by Zacks Equity Research

Inogen (INGN) gains from international revenues in Q2; slashes 2019 guidance.

Zacks Equity Research

Pacific Biosciences (PACB) Beats on Q2 Earnings & Revenues

by Zacks Equity Research

Pacific Biosciences (PACB) Q2 results gain from higher revenues and strong segmental performance. Contraction in gross margin remains a woe.

Zacks Equity Research

Allscripts (MDRX) Q2 Earnings Top Estimates, Revenues Lag

by Zacks Equity Research

Allscripts (MDRX) second-quarter results gain from growth in bookings and solid show by client services segment. Contraction in operating margin remains a woe.

Zacks Equity Research

Tandem (TNDM) Q2 Loss Narrower Than Expected, Sales Top Mark

by Zacks Equity Research

Tandem Diabetes' (TNDM) t:slim X2 Insulin pump's strength in domestic sales along with expansion in international markets during Q2 is encouraging.

Zacks Equity Research

Cardinal Health (CAH) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Cardinal Health (CAH) Q4 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, contraction in gross margin remains a concern.

Zacks Equity Research

LHC Group (LHCG) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

LHC Group (LHCG) second-quarter results benefit from home health and hospice admissions and higher revenues.

Zacks Equity Research

OPKO Health (OPK) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

OPKO Health (OPK) gains from RAYALDEE prescriptions in Q2.